DrugPatentWatch Database Preview

Cppi Cv Company Profile

« Back to Dashboard

What is the competitive landscape for CPPI CV, and when can generic versions of CPPI CV drugs launch?

CPPI CV has one approved drug.

There are three US patents protecting CPPI CV drugs.

Summary for Cppi Cv

US Patents:	3
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Cppi Cv

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cppi Cv	SUTENT	sunitinib malate	CAPSULE;ORAL	021938-004	Mar 31, 2009		RX	Yes	No
Cppi Cv	SUTENT	sunitinib malate	CAPSULE;ORAL	021938-004	Mar 31, 2009		RX	Yes	No	6,573,293		Y	Y
Cppi Cv	SUTENT	sunitinib malate	CAPSULE;ORAL	021938-002	Jan 26, 2006		RX	Yes	No	6,573,293		Y	Y
Cppi Cv	SUTENT	sunitinib malate	CAPSULE;ORAL	021938-002	Jan 26, 2006		RX	Yes	No
Cppi Cv	SUTENT	sunitinib malate	CAPSULE;ORAL	021938-001	Jan 26, 2006		RX	Yes	No	7,211,600

Paragraph IV (Patent) Challenges for CPPI CV drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	12.5 mg, 25 mg, 37.5 mg and 50 mg		2010-01-26

International Patents for Cppi Cv Drugs

Country	Document Number	Estimated Expiration
Czech Republic	20023081
Norway	2008019
Australia	784266
Luxembourg	91407
New Zealand	520640

Supplementary Protection Certificates for Cppi Cv Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2	Finland
657	Luxembourg		91657, EXPIRES: 20240923
C/GB08/007	United Kingdom		PRODUCT NAME: SUNITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE L- MALATE SALT; REGISTRATION NO/DATE: EU/1/06/347/001 - 003 20060724
2010 00004	Denmark		PRODUCT NAME: TOCERANIB, HERUNDER TOCERANIBPHOSPHAT
407	Luxembourg		91407, EXPIRES: 20210719

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cppi Cv